MediWound Expands Global Reach As Australia Grants Marketing Approval For NexoBrid®

MediWound Ltd., a global leader in developing next-generation enzymatic therapeutics for tissue repair, announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid. This innovative therapy is designed for the enzymatic removal of eschar in both adult and pediatric patients suffering from deep partial- and full-thickness thermal burns.

The approval in Australia further strengthens NexoBrid’s global footprint, with the product now authorized in 45 countries worldwide. It underscores the growing recognition of NexoBrid as a new standard of care in burn treatment, offering a non-surgical option for eschar removal and supporting improved outcomes for patients with severe burns.

Ofer Gonen, Chief Executive Officer of MediWound, stated, “The TGA approval of NexoBrid marks another important step in expanding access to innovative, non-surgical burn care. Together with our partner Balance Medical, we will ensure that burn centers across Australia have access to this therapy. Importantly, this milestone also opens the door to the broader Asia-Pacific region, where we see growing demand for advanced wound and burn treatments.”

Dr. Jason Brown, Director of the Queensland Adult Burn Service at the Royal Brisbane and Women’s Hospital, mentioned, “The approval of NexoBrid in Australia is a welcome milestone that will improve access to innovative burn-care solutions. In our clinical experience, NexoBrid enables rapid and selective eschar removal while preserving healthy dermis, providing clinicians with a much-needed non-surgical option to optimize outcomes for burn patients.”

In Australia, MediWound’s exclusive partner, Balance Medical, is preparing for the commercial launch of NexoBrid, which is expected to take place in the fourth quarter of 2025. To meet the increasing global demand for the product, MediWound is also advancing its manufacturing expansion, which is on schedule to be completed by the end of 2025. This expansion will ensure adequate supply to support both the Australian launch and the continued growth of NexoBrid in other markets.